

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/865,879
Filing Date:	May 25, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket No.	99,216-H

Sheet

1

of

1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
My	✓	Adamo et al., Endocrinology 131:1858-1866	
	✓	Chang et al., 1999, Cancer Res. 59:3761-3767	
	✓	DiSepio et al., 1998, Proc. Natl. Acad. Sci. USA 95:14811-14815	
	✓	Gucev et al., 1996, Cancer Res. 56:1545-1550	
	✓	Hayflick and Moorhead, 1961, Exp. Cell. Res. 25:585-621	
	✓	Huang et al., 2000, Molec. Cell. Endocrinol. 159:15-24	
	✓	Kato et al., 1996, Oncogene 12:1361-1364	
	✓	Liu et al., 2000 J. Cancer Res. Clin. Oncol. 126:85-90	
	✓	Miller et al., 1998, Cancer 83:1471-1482	
	✓	Noonan et al., 1990, Proc. Natl. Acad. Sci. USA 87:7160-7164	
	✓	Sugrue et al., 1997, Proc. Natl. Acad. Sci. USA 94:9648-9653	
	✓	Swisshelm et al., 1995, Proc. Natl. Acad. Sci. USA 92:4472-4476	
	✓	Uhrbom et al., 1997, Oncogene 15:505-514	
	✓	Vogt et al., 1998, Cell Growth Differ. 9:139-146	
	✓	Xu et al., 1997, Oncogene 15:2589-2596	
	✓	Zhu et al., 1997, Exp. Cell Res. 234:293-299	

TECH CENTER 1600/2900

JUL 08 2002

RECEIVED

Examiner
Signature

Misook Yu

Date
Considered


2-14-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

#8

Substitute for form 1449A/PTO		<div style="text-align: center;">  </div>		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application No.		09/865,879	
		Filing Date:		May 25, 2001	
		First Named Inventor		Roninson et al.	
		Group Art Unit		1642	
		Examiner Name		Misook Yu	
Sheet	1	of	2	Attorney Docket No.	99,216-H

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
my	✓	WO	98 08546	A	Inst Nat Sante Rech Med	March 5, 1998	RECEIVED JUL 16 2002 TECH CENTER 1600/2900	
↓	✓	WO	91 14695	A	Salk Inst for Biological Studi	October 3, 1991		
↓	✓	WO	96 23080	A	Allergan Inc.	August 1, 1996		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
my	✓	Cubbage et al., "Insulin-like Growth Factor Binding protein-3", Journal of Biological Chemistry, vol. 265, no. 21, July 15, 1990, 12642-12649.		
↓	✓	Hembree et al., "Retinoid X Receptor-Specific Retinoids Inhibit the Ability of Retinoic Acid Receptor-Specific Retinoids to Increase the Level of Insulin-Like Growth Factor Binding Protein-3 in Human Ectocervical Epithelial Cells", Cancer Research vol. 56, no. 8, April 15, 1996, pages 1794-1799.		
↓	✓	Shang et al., "Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells", Journal of Biological Chemistry, vol. 274, no. 25, June 18, 1999, pages 18005-18015,		
↓	✓	Han et al., "All-trans-retinoic acid increases transforming growth factor-beta-2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway", Journal of Biological Chemistry, vol. 272, no. 21, 1997, pages 13711-13716.		

Examiner Signature	<i>Misook Yu</i>	Date Considered	2/14/03
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

#9

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/865,879
Filing Date:	May 25, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket No.	99,216-H

Sheet

2

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
my		✓ SIMON et al., "Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion", Cancer Research, vol. 56, no. 23, 1996, pages 5369- 5374.	
		✓ KUMAR et al., "Setting up Reporter-Gene Based Assay Systems for Screening Anineoplastic Drugs" Pharmaceutical Technology, June 1, 1991, pages 39-43.	
		✓ ALBISTON et al., "Cloning and chracterization of the promoter for the rat insulin-like growth factor- binding protein-3 gene" Endocrinology, vol. 136, no. 2, 1995, pages 696-704.	
		✓ Heller et al., "Transcriptional regulation of the Bmp2 gene. Retinoic acid induction in F9 embyonal carcinoma cells and Saccharomyces cerevisiae", Journal of Biological Chemistry, vol. 274, no. 3, January 15, 1999, pages 1394-1400.	

Examiner
Signature

Date
Considered

2-14-03

RECEIVED

JUL 16 2002

TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231